Compounds > phenylalanine arginine beta-naphthylamide
Page last updated: 2024-11-08

phenylalanine arginine beta-naphthylamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

phenylalanine arginine beta-naphthylamide: a drug efflux pump inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID443301
CHEMBL ID56252
CHEBI ID6611
SCHEMBL ID1738816
MeSH IDM0377793

Synonyms (23)

Synonym
mc-207,110
n2-(l-phenylalanyl)-n1-(naphthalenyl)-l-arigninamide
MC2 ,
phenylalanine arginine beta-naphthylamide
chebi:6611 ,
phenylalanine arginine-beta-naphthylamide
CHEMBL56252 ,
(s)-2-((s)-2-amino-3-phenyl-propionylamino)-5-guanidino-pentanoic acid naphthalen-2-ylamide
bdbm50102053
1n-(2-naphthyl)-5-amino(imino)methylamino-2-[1-amino-2-phenyl-(1s)-ethylcarboxamido]-(2s)-pentanamide
(s)-2-((s)-2-amino-3-phenylpropanamido)-5-(diaminomethyleneamino)-n-(naphthalen-2-yl)pentanamide
(2s)-2-[[(2s)-2-amino-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)-n-naphthalen-2-ylpentanamide
AC1L9EE8 ,
ZNHUFUZDUQRKBB-VXKWHMMOSA-N
l-argininamide, l-phenylalanyl-n-2-naphthalenyl-
115871-02-8
SCHEMBL1738816
(2s)-2-[[(2s)-2-amino-3-phenyl-propanoyl]amino]-5-guanidino-n-(2-naphthyl)pentanamide
mc207110
l-phenylalanyl-n-naphthalen-2-yl-l-argininamide
phenylalanyl-arginine beta-naphthylamide
Q27107268
(s)-2-((s)-2-amino-3-phenylpropanamido)-5-guanidino-n-(naphthalen-2-yl)pentanamide

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" However, additional experiments are required to validate the robustness of this model after longer exposure periods and multiple dosing regimens, as well as in vivo."( Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa.
Comets, E; Couet, W; Grégoire, N; Grignon, C; Marliat, M; Ploy, MC; Raherison, S, 2010)		0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
peptideAmide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)IC50 (µMol)730.00000.00011.68479.3200AID69134
Phospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12IC50 (µMol)730.00000.01800.01800.0180AID69134
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (35)

Processvia Protein(s)Taxonomy
negative regulation of endothelial cell proliferationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte chemotaxis involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte migration involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
humoral immune responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of bone mineralizationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
dendritic cell migrationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose homeostasisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of fat cell differentiationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of insulin secretionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of vascular wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory response to woundingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cytokine production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cellular response to oxidative stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene A4 biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of sprouting angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxin biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cell shapePhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
peptidoglycan biosynthetic processPhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
cell divisionPhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
cell wall organizationPhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
cell wall macromolecule biosynthetic processPhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
arachidonate 5-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
hydrolase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
phospho-N-acetylmuramoyl-pentapeptide-transferase activityPhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
transferase activityPhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
phosphotransferase activity, for other substituted phosphate groupsPhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
metal ion bindingPhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimelyl-D-alanyl-D-alanine:undecaprenyl-phosphate transferase activityPhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
extracellular regionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular spacePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelope lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nucleoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear matrixPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear membranePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
secretory granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
perinuclear region of cytoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ficolin-1-rich granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
plasma membranePhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
membranePhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
plasma membranePhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (181)

Assay IDTitleYearJournalArticle
AID1714744Potentiation of erythromycin-induced antibacterial activity against AcrB deficient Escherichia coli BW25113 assessed as erythromycin MIC at 200 ug/ml incubated for 18 hrs under aerobic condition by checkerboard titration assay (Rvb = 32 ug/ml)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological activity evaluation of novel 4-subtituted 2-naphthamide derivatives as AcrB inhibitors.
AID723099Chemosensitization of wild type Enterobacter aerogenes ATCC 13048 assessed as decrease in PAbetaN MIC at 50 uM relative to control2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Search for new tools to combat Gram-negative resistant bacteria among amine derivatives of 5-arylidenehydantoin.
AID575169Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 1000 uM by spectrofluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID523254Antimicrobial activity against Klebsiella pneumoniae KP55 after 18 hrs by rapid INT colorimetric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.
AID1253893Antibacterial activity against Enterobacter sp. KCTC 2625 assessed as growth inhibition at 64 ug/ml after overnight incubation by broth microdilution method2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Antibacterial properties of 3-(phenylsulfonyl)-2-pyrazinecarbonitrile.
AID540817Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 5408 assessed as fold increase in nalidixic acid MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID1714762Potentiation of erythromycin-induced antibacterial activity against wild type Escherichia coli BW25113 assessed as erythromycin MIC at 200 ug/ml incubated for 18 hrs under aerobic condition by checkerboard titration assay (Rvb = 128 ug/ml)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological activity evaluation of novel 4-subtituted 2-naphthamide derivatives as AcrB inhibitors.
AID518954Antimicrobial activity against Escherichia coli TOP10 harboring pCR-Blunt2-TOPO carrying qnrB12 gene of Citrobacter werkmanii isolate CIT1 by broth macrodilution method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Novel variant of the qnrB gene, qnrB12, in Citrobacter werkmanii.
AID12089Stability in rat serum measured as % recovery at 10 mins2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Addressing the stability of C-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.
AID540839Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate NCTC 13349 assessed as fold increase in ciprofloxacin MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID1432102Inhibition of AcrB in wild-type drug resistant Escherichia coli BW25113 assessed as potentiation of chloramphenicol-induced antibacterial activity by measuring chloramphenicol MIC at 200 ug/ml after 18 hrs by checkerboard method (Rvb = 8 ug/ml)2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Evaluation of a series of 2-napthamide derivatives as inhibitors of the drug efflux pump AcrB for the reversal of antimicrobial resistance.
AID523126Antimicrobial activity against Enterobacter aerogenes EA289 after 18 hrs by rapid INT colorimetric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.
AID1666267Potentiation of chloramphenicol-induced antibacterial activity against Salmonella enterica subsp. enterica serovar Typhimurium BN10055 assessed as ratio of the chloramphenicol alone MIC to chloramphenicol MIC in presence of MIC/4 level of compound incubat2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
New Polyaminoisoprenyl Antibiotics Enhancers against Two Multidrug-Resistant Gram-Negative Bacteria from
AID727096Antibacterial activity against Enterobacter aerogenes Ea289 after 18 hrs by broth dilution method2013Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5
Polyamino geranic derivatives as new chemosensitizers to combat antibiotic resistant gram-negative bacteria.
AID726989Reduction of multidrug-resistant in Salmonella enterica Typhimurium BN10055 assessed as ratio of nalidixic acid MIC to nalidixic acid MIC in presence of compound at 38 uM by micro-broth dilution method2013Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5
Polyamino geranic derivatives as new chemosensitizers to combat antibiotic resistant gram-negative bacteria.
AID1714755Potentiation of chloramphenicol-induced antibacterial activity against wild type Escherichia coli BW25113 assessed as chloramphenicol MIC at 200 ug/ml incubated for 18 hrs under aerobic condition by checkerboard titration assay (Rvb = 16 ug/ml)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological activity evaluation of novel 4-subtituted 2-naphthamide derivatives as AcrB inhibitors.
AID1588241Potentiation of clarithromycin-induced antibacterial activity against Escherichia coli ATCC 25922 assessed as fold reduction in clarithromycin MIC at 12.5 uM incubated for 24 hrs by spectrophotometric based assay2019Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15
Advances in the structural studies of antibiotic potentiators against Escherichia coli.
AID540844Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 4931 assessed as fold increase in ciprofloxacin MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID563238Inhibition of MFS efflux pump in apramycin-resistant cmlR1 null mutant Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 75 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID727093Reduction of multidrug-resistant in Enterobacter aerogenes Ea289 assessed as ratio of chloramphenicol MIC to chloramphenicol MIC in presence of compound at 38 uM by micro-broth dilution method2013Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5
Polyamino geranic derivatives as new chemosensitizers to combat antibiotic resistant gram-negative bacteria.
AID541139Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate CUH60 assessed as fold increase in nalidixic acid MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID642454Antibacterial activity against Streptomyces coelicolor after 48 hrs2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Synthesis and evaluation of inhibitors of bacterial drug efflux pumps of the major facilitator superfamily.
AID151819Minimum inhibitory concentration of Levofloxacin in presence at a concentration of 1.25 ug/mL against PAM 1034.1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID518958Antimicrobial activity against Escherichia coli TOP10 by broth macrodilution method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Novel variant of the qnrB gene, qnrB12, in Citrobacter werkmanii.
AID1666266Potentiation of erythromycin-induced antibacterial activity against Enterobacter aerogenes Ea289 assessed as ratio of the erythromycin alone MIC to chloramphenicol MIC in presence of MIC/4 level of compound incubated for 18 hrs2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
New Polyaminoisoprenyl Antibiotics Enhancers against Two Multidrug-Resistant Gram-Negative Bacteria from
AID523110Antimicrobial activity against Escherichia coli ATCC 10536 after 18 hrs by rapid INT colorimetric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.
AID518957Antimicrobial activity against Citrobacter werkmanii isolate CIT3 harboring parC Leu88Gln mutant and qnrB12 gene by broth macrodilution method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Novel variant of the qnrB gene, qnrB12, in Citrobacter werkmanii.
AID523118Antimicrobial activity against tetracycline-resistant Escherichia coli AG100A after 18 hrs by rapid INT colorimetric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.
AID540849Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 104 assessed as fold increase in tetracycline MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID523130Antimicrobial activity against Enterobacter aerogenes EA298 after 18 hrs by rapid INT colorimetric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.
AID162924Minimum Inhibitory concentration required to inhibit the growth of Pseudomonas aeruginosa (strain PAM 1032)1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID162950Minimum inhibitory concentration of Levofloxacin in presence at a concentration of 2.5 ug/mL against PAM 10321999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID162953Minimum inhibitory concentration of Levofloxacin in presence at a concentration of 20 ug/mL against PAM 10321999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID575162Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 100 uM by spectrofluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID162956Minimum inhibitory concentration of Levofloxacin in presence at a concentration of 40 ug/mL against PAM 10321999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID540843Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate CUH60 assessed as fold increase in ciprofloxacin MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID523250Antimicrobial activity against Enterobacter aerogenes EA5 after 18 hrs by rapid INT colorimetric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.
AID163452In vitro minimum concentration of the efflux pump inhibitor required to reduce (potentiate) the MIC of fuoroquinolone levofloxacin 8-fold (LVFX)2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.
AID1714734Potentiation of TPP-induced antibacterial activity against AcrB deficient Escherichia coli BW25113 assessed as TPP MIC at 200 ug/ml incubated for 18 hrs under aerobic condition by checkerboard titration assay (Rvb = 256 ug/ml)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological activity evaluation of novel 4-subtituted 2-naphthamide derivatives as AcrB inhibitors.
AID1566605Potentiation of calrithromycin-induced antibacterial activity against Escherichia coli ATCC 25922 assessed as clarithromycin MIC at 50 ug/ml incubated for 24 hrs by microtiter plate reader analysis (Rvb = 64 microg/ml)2019European journal of medicinal chemistry, Sep-15, Volume: 178Structure-activity relationships of potentiators of the antibiotic activity of clarithromycin against Escherichia coli.
AID369669Inactivation of CmeABC efflux pump in Campylobacter jejuni 25-19 assessed as change in clarithromycin MIC by agar dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Contribution of the CmeABC efflux pump to macrolide and tetracycline resistance in Campylobacter jejuni.
AID523134Antimicrobial activity against Enterobacter aerogenes EA3 after 18 hrs by rapid INT colorimetric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.
AID541141Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 4931 assessed as fold increase in nalidixic acid MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID1588250Antibacterial activity against Escherichia coli ATCC 25922 incubated for 24 hrs by spectrophotometric based assay2019Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15
Advances in the structural studies of antibiotic potentiators against Escherichia coli.
AID540846Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 104-cip assessed as fold increase in ciprofloxacin MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID12092Stability in rat serum measured as % recovery at 3 mins2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Addressing the stability of C-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.
AID563241Inhibition of MFS efflux pump in apramycin-resistant cmlR2 null mutant Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 50 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID723106Antibacterial activity against Enterobacter aerogenes CM-64 overexpressing AcrAB-TolC assessed as growth inhibition after 18 hrs by CLSI broth dilution method2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Search for new tools to combat Gram-negative resistant bacteria among amine derivatives of 5-arylidenehydantoin.
AID1666270Potentiation of erythromycin-induced antibacterial activity against Salmonella enterica subsp. enterica serovar Typhimurium BN10055 assessed as ratio of the erythromycin alone MIC to chloramphenicol MIC in presence of MIC/4 level of compound incubated for2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
New Polyaminoisoprenyl Antibiotics Enhancers against Two Multidrug-Resistant Gram-Negative Bacteria from
AID540838Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate CUH52 assessed as fold increase in ciprofloxacin MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID151701Minimum inhibitory concentration of Levofloxacin in presence at a concentration of 10 ug/mL against PAM 1033.1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID1432103Inhibition of AcrB in wild-type drug resistant Escherichia coli BW25113 assessed as potentiation of tetraphenyl phosphonium chloride-induced antibacterial activity by measuring tetraphenyl phosphonium chloride MIC at 200 ug/ml after 18 hrs by checkerboard2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Evaluation of a series of 2-napthamide derivatives as inhibitors of the drug efflux pump AcrB for the reversal of antimicrobial resistance.
AID726995Reduction of multidrug-resistant in Salmonella enterica Typhimurium BN10055 assessed as ratio of chloramphenicol MIC to chloramphenicol MIC in presence of compound at 38 uM by micro-broth dilution method2013Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5
Polyamino geranic derivatives as new chemosensitizers to combat antibiotic resistant gram-negative bacteria.
AID642443Antibacterial activity against Streptomyces coelicolor at 25 ug/mL after 48 hrs2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Synthesis and evaluation of inhibitors of bacterial drug efflux pumps of the major facilitator superfamily.
AID518959Antimicrobial activity against Citrobacter werkmanii isolate CIT2 harboring qnrB12 gene by broth macrodilution method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Novel variant of the qnrB gene, qnrB12, in Citrobacter werkmanii.
AID541136Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 58 assessed as fold increase in nalidixic acid MIC relative to controlphenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID540848Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 5408-cip assessed as fold increase in ciprofloxacin MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID540859Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 5408-cip assessed as fold increase in ampicillin MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID540863Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 5408 assessed as fold increase in chloramphenicol MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID523120Antimicrobial activity against tetracycline-resistant Escherichia coli AG102 after 18 hrs by rapid INT colorimetric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.
AID162944Minimum inhibitory concentration of Levofloxacin in presence at a concentration of 1.25 ug/mL against PAM 10321999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID563235Inhibition of MFS efflux pump in apramycin-resistant cmlR1 null mutant Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 10 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID563236Inhibition of MFS efflux pump in apramycin-resistant cmlR1 null mutant Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 25 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID1666265Potentiation of doxycycline-induced antibacterial activity against Enterobacter aerogenes Ea289 assessed as ratio of the doxycycline alone MIC to chloramphenicol MIC in presence of MIC/4 level of compound incubated for 18 hrs2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
New Polyaminoisoprenyl Antibiotics Enhancers against Two Multidrug-Resistant Gram-Negative Bacteria from
AID151705Minimum inhibitory concentration of Levofloxacin in presence at a concentration of 50 ug/mL against PAM 1033.1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID540845Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 104 assessed as fold increase in ciprofloxacin MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID540862Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 104-cip assessed as fold increase in chloramphenicol MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID151817Minimum Inhibitory concentration required to reduce the MIC of levofloxacin by 8-fold against PAM 1033.1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID563231Inhibition of MFS efflux pump in Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 10 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID727001Reduction of multidrug-resistant in Enterobacter aerogenes Ea289 assessed as ratio of nalidixic acid MIC to nalidixic acid MIC in presence of compound at 38 uM by micro-broth dilution method2013Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5
Polyamino geranic derivatives as new chemosensitizers to combat antibiotic resistant gram-negative bacteria.
AID211872In vivo toxicity in mice i.v.2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.
AID163277Minimum inhibitory concentration required to inhibit growth of PAM 1032 strain of Pseudomonas aeruginosa that over expresses MexAB-Opr M efflux pump2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Addressing the stability of C-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.
AID523260Antimicrobial activity against Pseudomonas aeruginosa PA124 after 18 hrs by rapid INT colorimetric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.
AID1253890Antibacterial activity against Klebsiella pneumoniae ATCC 77326 assessed as growth inhibition at 64 ug/ml after overnight incubation by broth microdilution method2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Antibacterial properties of 3-(phenylsulfonyl)-2-pyrazinecarbonitrile.
AID518951Antimicrobial activity against nalidixic acid-resistant Citrobacter werkmanii isolate CIT1 harboring gyrA Thr83Ile, parC Ser57Thr mutant gene and qnrB12 gene by broth macrodilution method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Novel variant of the qnrB gene, qnrB12, in Citrobacter werkmanii.
AID523264Antimicrobial activity against Enterobacter cloacae Ec1194 after 18 hrs by rapid INT colorimetric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.
AID541146Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 104-cip assessed as fold increase in nalidixic acid MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID69615Antibacterial activity against Escherichia coli strain ATCC 259222001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
3-Arylpiperidines as potentiators of existing antibacterial agents.
AID1471313Inhibition of Pseudomonas aeruginosa MexAB-Oprm assessed as potentiation of levofloxacin-induced antibacterial activity at 50 ug/ml (Rvb = 16 ug/ml)2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.
AID1432104Effect on rifampicin-induced antibacterial activity against wild-type drug resistant Escherichia coli BW25113 assessed as rifampicin MIC at 200 ug/ml after 18 hrs by checkerboard method (Rvb = 16 ug/ml)2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Evaluation of a series of 2-napthamide derivatives as inhibitors of the drug efflux pump AcrB for the reversal of antimicrobial resistance.
AID563242Inhibition of MFS efflux pump in apramycin-resistant cmlR2 null mutant Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 75 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID540847Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 5408 assessed as fold increase in ciprofloxacin MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID540840Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 54 assessed as fold increase in ciprofloxacin MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID523114Antimicrobial activity against Escherichia coli AG100 after 18 hrs by rapid INT colorimetric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.
AID523262Antimicrobial activity against Enterobacter cloacae Ec07769 after 18 hrs by rapid INT colorimetric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.
AID1253891Antibacterial activity against Acinetobacter baumannii ATCC 17978 assessed as growth inhibition at 64 ug/ml after overnight incubation by broth microdilution method2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Antibacterial properties of 3-(phenylsulfonyl)-2-pyrazinecarbonitrile.
AID575163Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose by spectrofluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID151822Minimum inhibitory concentration of Levofloxacin in presence at a concentration of 20 ug/mL against PAM 1034.1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID523256Antimicrobial activity against Klebsiella pneumoniae KP63 after 18 hrs by rapid INT colorimetric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.
AID540855Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 5408 assessed as fold increase in trimethoprim-sulfamethoxazole MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID540864Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 5408-cip assessed as fold increase in chloramphenicol MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID523122Antimicrobial activity against Enterobacter aerogenes ATCC 13048 after 18 hrs by rapid INT colorimetric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.
AID151703Minimum inhibitory concentration of Levofloxacin in presence at a concentration of 20 ug/mL against PAM 1033.1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID540850Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 104-cip assessed as fold increase in tetracycline MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID557087Inhibition of multidrug resistance efflux pump in Enterobacter aerogenes isolate 17 assessed as increase in intracellular [14C]chloramphenicol accumulation relative to untreated control2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID162941Minimum inhibitory concentration of Levofloxacin in presence at a concentration of 0 ug/mL against PAM 10321999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID523252Antimicrobial activity against Klebsiella pneumoniae ATCC 11296 after 18 hrs by rapid INT colorimetric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.
AID575170Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 200 uM by spectrofluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID162773In vitro minimum concentration of the efflux pump inhibitor required to inhibit the growth of PAM 1723 a strain of Pseudomonas aeruginosa2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.
AID1566613Potentiation of levofloxacin-induced antibacterial activity against Pseudomonas aeruginosa assessed as concentration required to decrease levofloxacin MIC by 8 fold in presence of levofloxacin2019European journal of medicinal chemistry, Sep-15, Volume: 178Structure-activity relationships of potentiators of the antibiotic activity of clarithromycin against Escherichia coli.
AID523258Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by rapid INT colorimetric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.
AID151820Minimum inhibitory concentration of Levofloxacin in presence at a concentration of 10 ug/mL against PAM 1034.1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID518955Antimicrobial activity against Escherichia coli TOP10 harboring pCR-Blunt2-TOPO carrying qnrB12 gene of Citrobacter werkmanii isolate CIT2 by broth macrodilution method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Novel variant of the qnrB gene, qnrB12, in Citrobacter werkmanii.
AID540860Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 104 assessed as fold increase in chloramphenicol MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID563237Inhibition of MFS efflux pump in apramycin-resistant cmlR1 null mutant Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 50 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID518953Antimicrobial activity against Escherichia coli TOP10 harboring pCR-Blunt2-TOPO carrying qnrB12 gene of Citrobacter werkmanii isolate CIT3 by broth macrodilution method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Novel variant of the qnrB gene, qnrB12, in Citrobacter werkmanii.
AID540820Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 5408-cip assessed as fold increase in nalidixic acid MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID1225395Inhibition of AcrAB-TolC pump in Escherichia coli AG100 assessed as increase in intracellular H33342 fluorescence at 15.6 ug/ml after 60 mins by efflux inhibition assay2015Journal of natural products, Mar-27, Volume: 78, Issue:3
Enhancement of antibiotic activity against multidrug-resistant bacteria by the efflux pump inhibitor 3,4-dibromopyrrole-2,5-dione isolated from a Pseudoalteromonas sp.
AID540851Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 5408 assessed as fold increase in tetracycline MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID1427894Decrease in 1,2'-DiNaphtylAmine efflux in multidrug resistant Enterobacter aerogenes EA289 over-expressing AcrAB-TolC up to 256 uM after 18 hrs measured every 4 sec for 6 mins in presence of glucose by fluorescence assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New amphiphilic neamine conjugates bearing a metal binding motif active against MDR E. aerogenes Gram-negative bacteria.
AID151821Minimum inhibitory concentration of Levofloxacin in presence at a concentration of 2.5 ug/mL against PAM 1034.1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID523128Antimicrobial activity against Enterobacter aerogenes EA294 after 18 hrs by rapid INT colorimetric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.
AID541178Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate CUH52 assessed as fold increase in nalidixic acid MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID563245Antimicrobial activity against Streptomyces coelicolor after 48 hrs2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID212031In vivo minimum lethal dose causing lethality to >/=66% of the mice tested i.v.2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.
AID1566604Antibacterial activity against Escherichia coli ATCC 25922 incubated for 24 hrs by serial dilution method2019European journal of medicinal chemistry, Sep-15, Volume: 178Structure-activity relationships of potentiators of the antibiotic activity of clarithromycin against Escherichia coli.
AID563239Inhibition of MFS efflux pump in apramycin-resistant cmlR2 null mutant Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 10 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID369666Inactivation of CmeABC efflux pump in Campylobacter jejuni 25-19 assessed as change in erythromycin MIC by agar dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Contribution of the CmeABC efflux pump to macrolide and tetracycline resistance in Campylobacter jejuni.
AID727094Antibacterial activity against Salmonella enterica Typhimurium BN10055 harboring deltaacrB after 18 hrs by broth dilution method2013Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5
Polyamino geranic derivatives as new chemosensitizers to combat antibiotic resistant gram-negative bacteria.
AID12090Stability in rat serum measured as % recovery at 2 hr2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Addressing the stability of C-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.
AID563234Inhibition of MFS efflux pump in Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 75 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID12087Stability in rat serum measured as % recovery at 1 min2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Addressing the stability of C-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.
AID151699Minimum inhibitory concentration of Levofloxacin in presence at a concentration of 0 ug/mL against PAM 10331999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID563232Inhibition of MFS efflux pump in Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 25 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID151824Minimum inhibitory concentration of Levofloxacin in presence at a concentration of 5 ug/mL against PAM 1034.1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID563240Inhibition of MFS efflux pump in apramycin-resistant cmlR2 null mutant Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 25 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID523124Antimicrobial activity against Enterobacter aerogenes EA-CM64 after 18 hrs by rapid INT colorimetric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.
AID1666280Inhibition of AcrAB-TolC in Enterobacter aerogenes Ea289 assessed as retention of 1,2'diNA dye within bacterial membranes at 100 uM relative to control2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
New Polyaminoisoprenyl Antibiotics Enhancers against Two Multidrug-Resistant Gram-Negative Bacteria from
AID1253892Antibacterial activity against Pseudomonas aeruginosa PA14 assessed as growth inhibition at 64 ug/ml after overnight incubation by broth microdilution method2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Antibacterial properties of 3-(phenylsulfonyl)-2-pyrazinecarbonitrile.
AID540857Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 104 assessed as fold increase in ampicillin MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID540856Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 5408-cip assessed as fold increase in trimethoprim-sulfamethoxazole MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID541177Inhibition of AcrAB-TolC efflux pump in ciprofloxacin-resistant Salmonella enterica serovar enteritidis isolate CUH48 assessed as fold increase in nalidixic acid MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID575164Inhibition of acrAB AcrAB-TolC in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as [3H]TMG accumulation at 100 uM by scintillation counter method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID523112Antimicrobial activity against Escherichia coli ATCC 8739 after 18 hrs by rapid INT colorimetric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.
AID557089Inhibition of multidrug resistance efflux pump in Klebsiella pneumoniae isolate 14 assessed as increase in intracellular [14C]chloramphenicol accumulation relative to untreated control2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1666262Potentiation of chloramphenicol-induced antibacterial activity against Enterobacter aerogenes Ea289 assessed as ratio of the chloramphenicol alone MIC to chloramphenicol MIC in presence of MIC/4 level of compound incubated for 18 hrs2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
New Polyaminoisoprenyl Antibiotics Enhancers against Two Multidrug-Resistant Gram-Negative Bacteria from
AID563233Inhibition of MFS efflux pump in Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 50 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID540821Inhibition of AcrAB-TolC efflux pump in ciprofloxacin-resistant Salmonella enterica serovar enteritidis isolate CUH48 assessed as fold increase in ciprofloxacin MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID727097Antibacterial activity against Enterobacter aerogenes Ea294 harboring Ea289deltaacrB after 18 hrs by broth dilution method2013Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5
Polyamino geranic derivatives as new chemosensitizers to combat antibiotic resistant gram-negative bacteria.
AID557086Inhibition of multidrug resistance efflux pump in Enterobacter aerogenes isolate 13 assessed as increase in intracellular [14C]chloramphenicol accumulation relative to untreated control2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID163458Minimum Inhibitory concentration required to reduce the MIC of levofloxacin by 8-fold against PAM 10321999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID1432101Inhibition of AcrB in wild-type drug resistant Escherichia coli BW25113 assessed as potentiation of erythromycin-induced antibacterial activity by measuring erythromycin MIC at 200 ug/ml after 18 hrs by checkerboard method (Rvb = 128 ug/ml)2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Evaluation of a series of 2-napthamide derivatives as inhibitors of the drug efflux pump AcrB for the reversal of antimicrobial resistance.
AID151704Minimum inhibitory concentration of Levofloxacin in presence at a concentration of 40 ug/mL against PAM 1033.1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID151825Minimum Inhibitory concentration required to reduce the MIC of levofloxacin by 8-fold against PAM 1034.1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID541179Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate NCTC 13349 assessed as fold increase in nalidixic acid MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID541143Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 104 assessed as fold increase in nalidixic acid MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID162947Minimum inhibitory concentration of Levofloxacin in presence at a concentration of 10 ug/mL against PAM 10321999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID540854Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 104-cip assessed as fold increase in trimethoprim-sulfamethoxazole MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID540861Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 5408 assessed as fold increase in ampicillin MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID1714749Potentiation of rifampicin-induced antibacterial activity against wild type Escherichia coli BW25113 assessed as rifampicin MIC at 200 ug/ml incubated for 18 hrs under aerobic condition by checkerboard titration assay (Rvb = 16 ug/ml)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological activity evaluation of novel 4-subtituted 2-naphthamide derivatives as AcrB inhibitors.
AID523132Antimicrobial activity against Enterobacter aerogenes EA27 after 18 hrs by rapid INT colorimetric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.
AID540852Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 5408-cip assessed as fold increase in tetracycline MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID163453Minimum concentration of compound required to reduce the MIC of levofloxacin 8-fold in PAM 1032 strain of Pseudomonas aeruginosa that over expresses MexAB-OprM efflux pump2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Addressing the stability of C-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.
AID518956Antimicrobial activity against Escherichia coli TOP10 harboring empty vector pCR-Blunt2-TOPO by broth macrodilution method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Novel variant of the qnrB gene, qnrB12, in Citrobacter werkmanii.
AID557088Inhibition of multidrug resistance efflux pump in Klebsiella pneumoniae isolate 13 assessed as increase in intracellular [14C]chloramphenicol accumulation relative to untreated control2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID523116Antimicrobial activity against Escherichia coli AG100A after 18 hrs by rapid INT colorimetric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.
AID12094Stability in rat serum measured as % recovery at 5 mins2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Addressing the stability of C-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.
AID1666268Potentiation of nalidixic acid-induced antibacterial activity against Salmonella enterica subsp. enterica serovar Typhimurium BN10055 assessed as ratio of the nalidixic acid alone MIC to chloramphenicol MIC in presence of MIC/4 level of compound incubated2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
New Polyaminoisoprenyl Antibiotics Enhancers against Two Multidrug-Resistant Gram-Negative Bacteria from
AID1666264Potentiation of nalidixic acid-induced antibacterial activity against Enterobacter aerogenes Ea289 assessed as ratio of the nalidixic acid alone MIC to chloramphenicol MIC in presence of MIC/4 level of compound incubated for 18 hrs2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
New Polyaminoisoprenyl Antibiotics Enhancers against Two Multidrug-Resistant Gram-Negative Bacteria from
AID541137Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 51 assessed as fold increase in nalidixic acid MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID1714741Potentiation of chloramphenicol-induced antibacterial activity against AcrB deficient Escherichia coli BW25113 assessed as chloramphenicol MIC at 200 ug/ml incubated for 18 hrs under aerobic condition by checkerboard titration assay (Rvb = 2 ug/ml)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological activity evaluation of novel 4-subtituted 2-naphthamide derivatives as AcrB inhibitors.
AID642442Potentiation of chloramphenicol-induced antibacterial activity against Streptomyces coelicolor at 25 ug/mL after 48 hrs relative to control2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Synthesis and evaluation of inhibitors of bacterial drug efflux pumps of the major facilitator superfamily.
AID151702Minimum inhibitory concentration of Levofloxacin in presence at a concentration of 2.50 ug/mL against PAM 1033.1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID151700Minimum inhibitory concentration of Levofloxacin in presence at a concentration of 1.25 ug/mL against PAM 10331999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID540858Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 104-cip assessed as fold increase in ampicillin MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID1566607Potentiation of clarithromycin-induced antibacterial activity against Escherichia coli ATCC 25922 assessed as fold reduction in clarithromycin MIC at 50 ug/ml incubated for 24 hrs in presence of clarithromycin2019European journal of medicinal chemistry, Sep-15, Volume: 178Structure-activity relationships of potentiators of the antibiotic activity of clarithromycin against Escherichia coli.
AID727095Antibacterial activity against Salmonella enterica Typhimurium BN10055 after 18 hrs by broth dilution method2013Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5
Polyamino geranic derivatives as new chemosensitizers to combat antibiotic resistant gram-negative bacteria.
AID151818Minimum inhibitory concentration of Levofloxacin in presence at a concentration of 0 ug/mL against PAM 1034.1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID557085Inhibition of multidrug resistance efflux pump in Enterobacter aerogenes isolate 6 assessed as increase in intracellular [14C]chloramphenicol accumulation relative to untreated control2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID163758Volume of synergy by MacSynergy II 3-D analysis.1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID1471312Inhibition of Pseudomonas aeruginosa MexAB-Oprm assessed as potentiation of ciprofloxacin-induced antibacterial activity at 50 ug/ml (Rvb = 16 ug/ml)2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.
AID1666269Potentiation of doxycycline-induced antibacterial activity against Salmonella enterica subsp. enterica serovar Typhimurium BN10055 assessed as ratio of the doxycycline alone MIC to chloramphenicol MIC in presence of MIC/4 level of compound incubated for 12020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
New Polyaminoisoprenyl Antibiotics Enhancers against Two Multidrug-Resistant Gram-Negative Bacteria from
AID723107Antibacterial activity against wild type Enterobacter aerogenes ATCC 13048 assessed as growth inhibition after 18 hrs by CLSI broth dilution method2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Search for new tools to combat Gram-negative resistant bacteria among amine derivatives of 5-arylidenehydantoin.
AID541180Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 54 assessed as fold increase in nalidixic acid MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID151823Minimum inhibitory concentration of Levofloxacin in presence at a concentration of 40 ug/mL against PAM 1034.1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID540841Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 58 assessed as fold increase in ciprofloxacin MIC relative to controlphenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID540853Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 104 assessed as fold increase in trimethoprim-sulfamethoxazole MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID540842Inhibition of AcrAB-TolC efflux pump in Salmonella enterica serovar enteritidis isolate 51 assessed as fold increase in ciprofloxacin MIC relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
AID163082Minimum inhibitory concentration of Levofloxacin in presence at a concentration of 5 ug/mL against PAM 10321999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
AID69134Inhibitory activity against accumulation of [14C]-labeled Linezolid within wild-type Escherichia coli K12 cells2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
3-Arylpiperidines as potentiators of existing antibacterial agents.
AID1714751Potentiation of TPP-induced antibacterial activity against wild type Escherichia coli BW25113 assessed as TPP MIC at 200 ug/ml incubated for 18 hrs under aerobic condition by checkerboard titration assay (Rvb = 1024 ug/ml)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological activity evaluation of novel 4-subtituted 2-naphthamide derivatives as AcrB inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (94)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (1.06)18.2507
2000's36 (38.30)29.6817
2010's48 (51.06)24.3611
2020's9 (9.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.66 (24.57)
Research Supply Index4.56 (2.92)
Research Growth Index6.59 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (3.16%)6.00%
Case Studies1 (1.05%)4.05%
Observational0 (0.00%)0.25%
Other91 (95.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1,10-phenanthroline
1,10-phenanthroline: RN given refers to parent cpd; inhibits Zn-dependent metalloproteinases		2.0510phenanthrolineEC 2.7.1.1 (hexokinase) inhibitor;
EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor
1-anilino-8-naphthalenesulfonate
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.		2.0810aminonaphthalene;
naphthalenesulfonic acid		fluorescent probe
2,2'-dipyridyl
2,2'-Dipyridyl: A reagent used for the determination of iron.. 2,2'-bipyridine : A bipyridine in which the two pyridine moieties are linked by a bond between positions C-2 and C-2'.		2.0510bipyridinechelator;
ferroptosis inhibitor
2,4-dinitrophenol
2,4-Dinitrophenol: A toxic dye, chemically related to trinitrophenol (picric acid), used in biochemical studies of oxidative processes where it uncouples oxidative phosphorylation. It is also used as a metabolic stimulant. (Stedman, 26th ed). dinitrophenol : Members of the class of nitrophenol carrying two nitro substituents.. 2,4-dinitrophenol : A dinitrophenol having the nitro groups at the 2- and 4-positions.		2.1110dinitrophenolallergen;
antiseptic drug;
bacterial xenobiotic metabolite;
geroprotector;
oxidative phosphorylation inhibitor
acetohydroxamic acid
acetohydroxamic acid: urease inhibitor. oxime : Compounds of structure R2C=NOH derived from condensation of aldehydes or ketones with hydroxylamine. Oximes from aldehydes may be called aldoximes; those from ketones may be called ketoximes.. N-hydroxyacetimidic acid : A carbohydroximic acid consisting of acetimidic acid having a hydroxy group attached to the imide nitrogen.. acetohydroxamic acid : A member of the class of acetohydroxamic acids that is acetamide in which one of the amino hydrogens has been replaced by a hydroxy group.		2.0510acetohydroxamic acids;
carbohydroximic acid		algal metabolite;
EC 3.5.1.5 (urease) inhibitor
aztreonam
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.. aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.		2.1310
benzyl isothiocyanate
benzyl isothiocyanate: inhibits carcinogen-induced neoplasia; structure in Negwer, 5th ed, #715; also promotes urinary bladder carcinoma		2.2510benzenes;
isothiocyanate		antibacterial drug
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		2.0310aromatic ether;
nitrile;
polyether;
tertiary amino compound
carbonyl cyanide m-chlorophenyl hydrazone
Carbonyl Cyanide m-Chlorophenyl Hydrazone: A proton ionophore. It is commonly used as an uncoupling agent and inhibitor of photosynthesis because of its effects on mitochondrial and chloroplast membranes.. CCCP : A member of the class of monochlorobenzenes that is benzene substituted by 2-(1,3-dinitrilopropan-2-ylidene)hydrazinyl and chloro groups at positions 1 and 3, respectively. It is a mitochondrial depolarizing agent that induces reactive oxygen species mediated cell death.		3.3460hydrazone;
monochlorobenzenes;
nitrile		antibacterial agent;
geroprotector;
ionophore
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		4.32180aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
fleroxacin
Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.. fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.		2.1510difluorobenzene;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
quinolines		antibacterial drug;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
ethidium
Ethidium: A trypanocidal agent and possible antiviral agent that is widely used in experimental cell biology and biochemistry. Ethidium has several experimentally useful properties including binding to nucleic acids, noncompetitive inhibition of nicotinic acetylcholine receptors, and fluorescence among others. It is most commonly used as the bromide.. ethidium : The fluorescent compound widely used in experimental cell biology and biochemistry to reveal double-stranded DNA and RNA.		2.0310phenanthridinesfluorochrome;
intercalator
metronidazole
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.		2.0610C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
nalidixic acid
[no description available]		3.66901,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor
niclosamide
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48). niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.		2.4110benzamides;
C-nitro compound;
monochlorobenzenes;
salicylanilides;
secondary carboxamide		anthelminthic drug;
anticoronaviral agent;
antiparasitic agent;
apoptosis inducer;
molluscicide;
piscicide;
STAT3 inhibitor
norfloxacin
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.		2.7430fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
ofloxacin
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.		2.72303-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
piperazine
[no description available]		2.0710azacycloalkane;
piperazines;
saturated organic heteromonocyclic parent		anthelminthic drug
gatifloxacin
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.		2.0310N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
triclosan
[no description available]		2.0810aromatic ether;
dichlorobenzene;
monochlorobenzenes;
phenols		antibacterial agent;
antimalarial;
drug allergen;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
fungicide;
persistent organic pollutant;
xenobiotic
trimethoprim
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.		2.0610aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
reserpine
Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.		3.360alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
chloramphenicol
Amphenicol: Chloramphenicol and its derivatives.		4.01130C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
kanamycin a
Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.		2.4820kanamycinsbacterial metabolite
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		2.0510monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
edetic acid
Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.		2.5220ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector
cloxacillin
Cloxacillin: A semi-synthetic antibiotic that is a chlorinated derivative of OXACILLIN.. cloxacillin : A semisynthetic penicillin antibiotic carrying a 3-(2-chlorophenyl)-5-methylisoxazole-4-carboxamido group at position 6.		2.0310penicillin allergen;
penicillin;
semisynthetic derivative		antibacterial agent;
antibacterial drug
phenylalanine
Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.		2.3110amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
oxacillin
Oxacillin: An antibiotic similar to FLUCLOXACILLIN used in resistant staphylococci infections.. oxacillin : A penicillin antibiotic carrying a 5-methyl-3-phenylisoxazole-4-carboxamide group at position 6beta.		2.5220penicillinantibacterial agent;
antibacterial drug
ampicillin
Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.		2.7630beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
arginine
Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.		2.5720arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
pyronine
Pyronine: Xanthene dye used as a bacterial and biological stain. Synonyms: Pyronin; Pyronine G; Pyronine Y. Use also for Pyronine B. which is diethyl-rather than dimethylamino-.. pyronin Y : An organic chloride salt having 6-(dimethylamino)-N,N-dimethyl-3H-xanthen-3-iminium as the cation. Used with methyl green to selectively demonstrate RNA (red) in contrast to DNA (green) with the Unna-Pappenheim method.		2.0310iminium salt;
organic chloride salt		histological dye
cyclohexane
Cyclohexane: C6H12. cyclohexane : An alicyclic hydrocarbon comprising a ring of six carbon atoms; the cyclic form of hexane, used as a raw material in the manufacture of nylon.		2.0610cycloalkane;
volatile organic compound		non-polar solvent
nafcillin
Nafcillin: A semi-synthetic antibiotic related to penicillin.. nafcillin : A penicillin in which the substituent at position 6 of the penam ring is a (2-ethoxy-1-naphthoyl)amino group.		2.0510penicillin allergen;
penicillin		antibacterial drug
catechin
Catechin: An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.. catechin : Members of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.. rac-catechin : A racemate comprising equimolar amounts of (+)- and (-)-catechin. (+)-catechin : The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.		2.5120catechinantioxidant;
plant metabolite
pyrazines
Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.		2.1110diazine;
pyrazines		Daphnia magna metabolite
erythromycin
Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.		3.6690cyclic ketone;
erythromycin
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		2.1110glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
spectinomycin
Spectinomycin: An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of GONORRHEA.. spectinomycin dihydrochloride : A hydrochloride obtained by combining spectinomycin with two molar equivalents of hydrochloric acid. An antibiotic that is active against gram-negative bacteria and used (as its pentahydrate) to treat gonorrhea.. spectinomycin : A pyranobenzodioxin and antibiotic that is active against gram-negative bacteria and used (as its dihydrochloride pentahydrate) to treat gonorrhea. It is produced by the bacterium Streptomyces spectabilis.		2.0510cyclic acetal;
cyclic hemiketal;
cyclic ketone;
pyranobenzodioxin;
secondary alcohol;
secondary amino compound		antibacterial drug;
antimicrobial agent;
bacterial metabolite
streptomycin
[no description available]		2.4920antibiotic antifungal drug;
antibiotic fungicide;
streptomycins		antibacterial drug;
antifungal agrochemical;
antimicrobial agent;
antimicrobial drug;
bacterial metabolite;
protein synthesis inhibitor
deuterium
Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.		2.2510dihydrogen
thiamphenicol
[no description available]		2.7330monocarboxylic acid amide;
sulfone		antimicrobial agent;
immunosuppressive agent
piperacillin
Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.		2.5120penicillin allergen;
penicillin		antibacterial drug
sparfloxacin
[no description available]		2.4720fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone
epigallocatechin gallate
epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.		2.5120flavans;
gallate ester;
polyphenol		antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite
cephalosporin c
cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.		210cephalosporinfungal metabolite
neamine
neamine: fragment of NEOMYCIN B; structure in first source. neamine : 2-Deoxy-D-streptamine glycosylated at the 4-oxygen with a 6-amino-alpha-D-glucosaminyl group.		2.15102,6-dideoxy-alpha-D-glucoside;
aminoglycoside		antibacterial agent
2-naphthylamide
naphthalene-2-carboxamide: structure in first source. naphthalene-2-carboxamide : A naphthalenecarboxamide resulting from the formal condensation of the carboxy group of 2-naphthoic acid with ammonia.		2.6320naphthalenecarboxamide
clarithromycin
Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.		3.1550macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
imipenem, anhydrous
Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.		2.7830beta-lactam antibiotic allergen;
carbapenems;
zwitterion		antibacterial drug
florfenicol
florfenicol: structure given in first source. florfenicol : A carboxamide that is the N-dichloroacetyl derivative of (1R,2S)-2-amino-3-fluoro-1-[4-(methanesulfonyl)phenyl]propan-1-ol. A synthetic veterinary antibiotic that is used for treatment of bovine respiratory disease and foot rot; also used in aquaculture.		2.7330organochlorine compound;
organofluorine compound;
secondary alcohol;
secondary carboxamide;
sulfone		antimicrobial agent
tazobactam
Tazobactam: A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria.. tazobactam : A member of the class of penicillanic acids that is sulbactam in which one of the exocyclic methyl hydrogens is replaced by a 1,2,3-triazol-1-yl group; used (in the form of its sodium salt) in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections.		2.1510penicillanic acids;
triazoles		antiinfective agent;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
pyrrolomycin d
pyrrolomycin D: from Streptomyces strain SF-2080; structure given in first source		2.1510
beta-lactams
2-azetidinone: structure in first source. azetidin-2-one : An unsubstituted beta-lactam compound.. beta-lactam : A lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon.		2.7730beta-lactam antibiotic allergen;
beta-lactam
levofloxacin
Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.		3.43709-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
ertapenem
Ertapenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.. ertapenem : Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract.		2.1310carbapenemcarboxylic acid;
pyrrolidinecarboxamide		antibacterial drug
arginine beta-naphthylamide
arginine beta-naphthylamide: RN given refers to (S)-isomer. L-arginine 2-naphthylamide : An L-arginine derivative that is the amide obtained by formal condensation of the carboxy group of L-arginine with the amino group of 2-naphthylamine.		2.110amino acid amide;
L-arginine derivative;
N-(2-naphthyl)carboxamide		chromogenic compound
moxifloxacin
Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.		2.0310aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
tetraphenylphosphonium chloride
[no description available]		2.0510
deoxycholic acid
Deoxycholic Acid: A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.. deoxycholic acid : A bile acid that is 5beta-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 12 respectively.		2.9740bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human blood serum metabolite
trimethoprim, sulfamethoxazole drug combination
Trimethoprim, Sulfamethoxazole Drug Combination: A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.. co-trimoxazole : A two-component mixture comprising trimethoprim and sulfamethoxazole.		2.110
1,2,6-tri-o-galloyl-beta-d-glucopyranose
1,2,6-tri-O-galloyl-beta-D-glucopyranose: from Terminalia chebula fruits, effective against multidrug-resistant uropathogens; structure in first source. 1,2,6-tris-O-galloyl-beta-D-glucose : A galloyl-beta-D-glucose compound having the galloyl groups in the 1-, 2- and 6-positions.		2.110gallate ester;
galloyl beta-D-glucose
meropenem
Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.		2.1110alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide		antibacterial agent;
antibacterial drug;
drug allergen
cefoxitin
Cefoxitin: A semisynthetic cephamycin antibiotic resistant to beta-lactamase.. cefoxitin : A semisynthetic cephamycin antibiotic which, in addition to the methoxy group at the 7alpha position, has 2-thienylacetamido and carbamoyloxymethyl side-groups. It is resistant to beta-lactamase.		2.0510beta-lactam antibiotic allergen;
cephalosporin;
cephamycin;
semisynthetic derivative		antibacterial drug
linezolid
[no description available]		2.0510acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
clindamycin
Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.		2.0610
zithromax
Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.		2.4720macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
geraniol
[no description available]		2.05103,7-dimethylocta-2,6-dien-1-ol;
monoterpenoid;
primary alcohol		allergen;
fragrance;
plant metabolite;
volatile oil component
1-(1-naphthylmethyl)piperazine
[no description available]		3.86110
capsaicin
ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.		2.1510capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
thiourea
Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.		2.110one-carbon compound;
thioureas;
ureas		antioxidant;
chromophore
fusidic acid
Fusidic Acid: An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed). It acts by inhibiting translocation during protein synthesis.. fusidic acid : A steroid antibiotic that is isolated from the fermentation broth of Fusidium coccineum.		2.051011alpha-hydroxy steroid;
3alpha-hydroxy steroid;
alpha,beta-unsaturated monocarboxylic acid;
steroid acid;
steroid antibiotic;
sterol ester		EC 2.7.1.33 (pantothenate kinase) inhibitor;
Escherichia coli metabolite;
protein synthesis inhibitor
sodium dodecyl sulfate
Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.. sodium dodecyl sulfate : An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.		2.0510organic sodium saltdetergent;
protein denaturant
isobavachalcone
isobavachalcone: RN given for (E)-isomer; structure in first source. isobavachalcone : A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 4, 2' and 4' and a prenyl group at position 3'.		2.0510chalcones;
polyphenol		antibacterial agent;
metabolite;
platelet aggregation inhibitor
cefepime
Cefepime: A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.. cefepime : A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		2.0510cephalosporin;
oxime O-ether		antibacterial drug
ceftazidime
[no description available]		2.4920cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
cyanine dye 1
cyanine dye 1: RN given refers to iodide; structure		2.0810
carbocyanines
Carbocyanines: Compounds that contain three methine groups. They are frequently used as cationic dyes used for differential staining of biological materials.		2.0810cyanine dye;
organic iodide salt		fluorochrome
nitrocefin
nitrocefin: chromogenic cephalosporin used for detection of beta-lactamase activity; Cefinase is name for nitrocefin on paper disc; RN given refers to (6R-(3(E),6 alpha,7 beta))-isomer; structure for mono-Na salt in second source		210
avibactam
avibactam : A member of the class of azabicycloalkanes that is (2S,5R)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide in which the amino hydrogen at position 6 is replaced by a sulfooxy group. Used (in the form of its sodium salt) in combination with ceftazidime pentahydrate for the treatment of complicated urinary tract infections including pyelonephritis.		2.1310azabicycloalkane;
hydroxylamine O-sulfonic acid;
monocarboxylic acid amide;
ureas		antibacterial drug;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
gentamicin sulfate
[no description available]		2.0510
polymyxin b(1)
[no description available]		2.6320
ru 66647
telithromycin: a ketolide; semisynthetic derivative of erythromycin with cycling of the C11-12 positions to form a carbamate ring to avoid acquired resistance to macrolides; binds 70S bacterial rRNA, specifically to the 23S part (23S RIBOSOMAL RNA), preventing protein synthesis;		2.0210
rifamycins
[no description available]		2.0810
cellulose
DEAE-Cellulose: Cellulose derivative used in chromatography, as ion-exchange material, and for various industrial applications.		2.0810glycoside
sodium salicylate
[no description available]		2.0410organic molecular entity
d13-9001
D13-9001: structure in first source		2.0510
nxl 104
avibactam sodium : An organic sodium salt that is the monosodium salt of avibactam. Used in combination with ceftazidime pentahydrate for the treatment of complicated urinary tract infections including pyelonephritis.		2.1510organic sodium saltantibacterial drug;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
piperidines
Piperidines: A family of hexahydropyridines.		2.0510
colistin
Colistin: Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.. colistin : A multi-component mixture comprising mostly of colistin A (R = Me) and B (R = H), with small amounts of colistin C and other polymyxins, produced by certain strains of Bacillus polymyxa var. colistinus. An antibiotic, it is used as its sulfate salt (for oral or topical use) or as the sodium salt of the N-methylsulfonic acid derivative (the injectable form) in the treatment of severe Gram-negative infections, partiularly those due to Pseudomonas aeruginosa.		2.1110
4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-n-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide
4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide: inhibits phosphopantetheinyl transferase; structure in first source		2.110
novobiocin
Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.		2.520carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols		antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent
tetracycline
Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.		3.3260
chlortetracycline
Chlortetracycline: A TETRACYCLINE with a 7-chloro substitution.. chlortetracycline : A member of the class of tetracyclines with formula C22H23ClN2O8 isolated from Streptomyces aureofaciens.		2.4520
minocycline
Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.		4.0840
tigecycline
[no description available]		3.5420
rpx7009
RPX7009: a beta-lactamase inhibitor; structure in first source		2.1510
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		3.5520cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Cronobacter Infections
[description not available]		03.3360
Enterobacteriaceae Infections
Infections with bacteria of the family ENTEROBACTERIACEAE.		03.3360
Infections, Pseudomonas
[description not available]		03.1850
Pseudomonas Infections
Infections with bacteria of the genus PSEUDOMONAS.		03.1850
Salmonella Infections, Animal
Infections in animals with bacteria of the genus SALMONELLA.		02.2510
Acinetobacter Infections
Infections with bacteria of the genus ACINETOBACTER.		03.7130
Diathesis
[description not available]		02.3110
Vibrio cholerae Infection
[description not available]		02.3110
Cholera
An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is VIBRIO CHOLERAE. This condition can lead to severe dehydration in a matter of hours unless quickly treated.		02.3110
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		02.4920
Mastitis, Bovine
INFLAMMATION of the UDDER in cows.		02.110
Cystic Fibrosis of Pancreas
[description not available]		02.0510
Cystic Fibrosis
An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.		02.0510
Health Care Associated Infection
[description not available]		02.0510
Cross Infection
Any infection which a patient contracts in a health-care institution.		02.0510
Infections, Helicobacter
[description not available]		02.0510
Helicobacter Infections
Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.		02.0510
Campylobacter Infection
[description not available]		02.4620
Infections, Salmonella
[description not available]		02.0210
E coli Infections
[description not available]		02.0310
Escherichia coli Infections
Infections with bacteria of the species ESCHERICHIA COLI.		02.0310
Bacteremia
The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.		02.0310
Bacterial Disease
[description not available]		0210
Bacterial Infections
Infections by bacteria, general or unspecified.		0210